Eltrombopag (SB-497115, GlaxoSmithKline) is a new, small-molecule, nonpeptide, oral platelet growth factor that acts as a thrombopoietin-receptor agonist.

Eltrombopag (Promacta) is an oral thrombopoietin mimetic that binds to c-MPL, promoting megakaryopoiesis and release of platelets from mature megakaryocytes. 12 Eltrombopag increases platelet ...

SAN DIEGO — Eltrombopag conferred a higher rate of durable platelet response in the absence of rescue treatments than standard first-line treatments for children with newly diagnosed immune ...

However, eltrombopag and romiplostim should never be considered as front-line treatment of the disease, George said. “These drugs are very expensive and they are maintenance therapies,” he said.

This trial suggests that eltrombopag, especially at a daily dose of 75 mg, is effective in raising platelet counts in cirrhotic HCV-positive patients, and it seems to be safe.

While eltrombopag, a small-molecule non-peptide thrombopoietin receptor agonist, has been approved for children with chronic ITP, its efficacy in newly diagnosed pediatric ITP is unknown.

Eltrombopag is an orally bioavailable, small molecule acting as a TPO-R agonist, approved for the treatment of thrombocytopenia of chronic immune thrombocytopenic purpura, chronic hepatitis C virus ...

PHILADELPHIA, Nov. 21 -- The FDA has approved oral eltrombopag (Promacta) for adult patients with refractory chronic immune thrombocytopenic purpura, the drug's maker announced. Eltrombopag's ...

4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of eltrombopag, having considered evidence on the nature of chronic immune thrombocytopenia (ITP) and the ...

While eltrombopag, a small-molecule non-peptide thrombopoietin receptor agonist, has been approved for children with chronic ITP, its efficacy in newly diagnosed pediatric ITP is unknown.